Research Shows Improvement In Research-Based Pharma Industry Reputation
The International Federation of Pharmaceutical Manufacturers and Associations commissioned Ipsos to perform the research.
New annual research conducted by Ipsos for the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), shows that the research-based pharmaceutical industry has garnered a positive reputation, with its pandemic response and the impact of its innovations seen as key strengths by the general public, with innovation and efforts to broaden access to vaccines and treatments being seen as drivers of positive sentiment among those surveyed. The survey was conducted in 11 countries polling a representative sample of 11,000 people across both high and lower-income countries. The study was commissioned by the International IFPMA.
The survey underlines that industry’s response to COVID-19 has contributed to a positive trend in terms of reputation. The public is highly positive about the sector’s ongoing pandemic response, with more than half of respondents considering that the pharmaceutical industry works well with governments, international organisations, and other institutions to make their vaccines, medicines, and treatments available to as many people as possible, worldwide. The public has an expectation that industry will continue to innovate against COVID, and have faith it will prepare, respond, and deliver during future pandemics.
Continue reading this story here.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
